Brian Powl - Jul 5, 2023 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role: Chief Commercial Officer
Signature: /s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol: FATE
Transactions as of: Jul 5, 2023
Transactions value $: -$18,769
Form type: 4
Date filed: 7/6/2023, 05:19 PM
Previous filing: Feb 7, 2023
Next filing: Aug 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FATE	Common Stock	Sale	-$18.8K	-3.85K	-8.56%	$4.87	41.1K	Jul 5, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
F2	Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote.

Content

Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.

Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote.